Neurological Indication definition
Examples of Neurological Indication in a sentence
The co-promotion by the Parties with respect to any Product that has received a Regulatory Approval for a Neurological Indication or a Psychiatric Indication and has been the subject of a Launch in the US shall extend to any additional Neurological Indication or Psychiatric Indication which Roche determines to obtain the applicable Regulatory Approvals to market and sell the Product in the US for such additional Neurological Indication or Psychiatric Indication.
If Roche has received all Regulatory Approvals in the US to market and sell a Product for a Neurological Indication or a Psychiatric Indication and an Other Indication and is the subject of co-promotion by Memory, the Parties shall negotiate in good faith and agree upon an equitable adjustment to the compensation and cost-sharing provisions set forth in the Co-Promotion Agreement, to account for the fact that Memory shall not have any right or obligation to co-promote such Product for the Other Indication.
Roche shall pay to Memory the following payments for a given Product having a Regulatory Approval for a Neurological Indication, based upon the Net Sales of such Product, which such Net Sales shall be subject to adjustment as provided in this Article 5.
In such case, Memory shall be responsible for [*] percent ([*]%) of the cost of obtaining such Regulatory Approvals, including the cost of conducting clinical trials, which shall be paid by Memory to Roche promptly after Roche obtains all Regulatory Approvals for such Product in the US to enable Roche and Memory to market and sell such Product in the US for such additional Neurological Indication or Psychiatric Indication.
For example, if Memory has commenced the Initiation of Phase I with respect to one (1) Product for a Neurological Indication and one (1) Product for a Psychiatric Indication at the end of such [*] year period, then Roche shall have the right to designate as Memory Compounds up to [*] additional compounds which are nicotinic alpha-7 agonists in preclinical development by Memory.
If Roche (alone or with its Affiliates) develops a Non-Memory Compound for a Neurological Indication or a Psychiatric Indication, then Roche shall pay Memory for such Non-Memory Compound achieving the Events of Sections 4.3(a) and 4.3(b) as if such Non-Memory Compound were a Product except (i) Roche shall pay [*] percent ([*]%) of such payments related to IND, Phase II and Phase III Events, and (ii) [*] percent ([*]%) of all other payments provided under Section 4.3(a) and 4.3(b).
Notwithstanding anything to the contrary contained in this Section 4.4, in no event shall the payment by Roche to Memory with respect to the occurrence of the [*] be less than [*] dollars ($[*]) for a Product for a Neurological Indication or [*] dollars ($[*]) for a Product for a Psychiatric Indication.
The right of Roche to obtain a License as provided in this Section 2.1 shall be exercisable by Roche giving written notice to Memory and making or having made payment to Memory of all License Rights Maintenance Fees for such Product under Section 4.4 with respect to a License for a Product for a Neurological Indication or a Psychiatric Indication.
Roche shall pay to Memory royalties for a given 3454 Product having a Regulatory Approval for an Other Indication, in an amount equal to [*] of the royalties otherwise payable for such 3454 Product having a Regulatory Approval for a Neurological Indication based upon the Net Sales of such Product, which royalty rate shall be subject to adjustment as provided in this Article 5.
Notwithstanding anything to the contrary, payment shall be made pursuant to this Section 5.9 with respect to a Product for a Neurological Indication or a Psychiatric Indication only if such Product contains a different Memory Compound than any Memory Compound contained in a Product for which payment previously has been made pursuant to this Section 5.9.